Brief: Cantargia Gets Positive EMA Opinion For Orphan Designation Of Nadunolimab For Treatment Of Pancreatic Cancer
14/10/2021 07:36
Oct 14 (Reuters) - Cantargia AB CANTA.ST :
* CANTARGIA RECEIVES POSITIVE EMA OPINION FOR ORPHAN
DESIGNATION
OF NADUNOLIMAB FOR TREATMENT OF PANCREATIC CANCER
* EUROPEAN COMMISSION IS NOW EXPECTED TO GRANT ORPHAN
DESIGNATION
* COMP AT EMA HAS ISSUED A POSITIVE OPINION FOR ORPHAN
DESIGNATION
OF CAN04 FOR TREATMENT OF PANCREATIC CANCER
Source text for Eikon: ID:nWkrbbvhCK
Further company coverage: CANTA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Cantargia AB
See all newsBrief: Cantargia Publishes Nadunolimab CANFOUR Study Data
Brief: Cantargia Announces Outcome Of Rights Issue, Raising About SEK 75 Mln
Brief: Cantargia Carries Out Rights Issue, Enters Loan Agreement
Brief: Cantargia Q1 Operating Loss Narrows To SEK 36.9 Mln
Brief: Cantargia: Early Results From Phase 1B/2A Nadunolimab Trial In MDS And AML